Mind Medicine Inc
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials… Read more
Mind Medicine Inc (MNMD) - Total Assets
Latest total assets as of September 2025: $236.92 Million USD
Based on the latest financial reports, Mind Medicine Inc (MNMD) holds total assets worth $236.92 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Mind Medicine Inc - Total Assets Trend (2015–2024)
This chart illustrates how Mind Medicine Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Mind Medicine Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Mind Medicine Inc's total assets of $236.92 Million consist of 93.2% current assets and 6.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 90.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $19.92 Million | 6.6% |
Asset Composition Trend (2015–2024)
This chart illustrates how Mind Medicine Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Mind Medicine Inc's current assets represent 93.2% of total assets in 2024, an increase from 63.9% in 2015.
- Cash Position: Cash and equivalents constituted 90.6% of total assets in 2024, up from 1.6% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is goodwill at 6.6% of total assets.
Mind Medicine Inc Competitors by Total Assets
Key competitors of Mind Medicine Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Mind Medicine Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Mind Medicine Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Mind Medicine Inc is currently not profitable relative to its asset base.
Mind Medicine Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.30 | 9.00 | 27.10 |
| Quick Ratio | 3.30 | 9.00 | 27.10 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $150.43 Million | $ 266.09 Million | $ 78.51 Million |
Mind Medicine Inc - Advanced Valuation Insights
This section examines the relationship between Mind Medicine Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 12.91 |
| Latest Market Cap to Assets Ratio | 4.83 |
| Asset Growth Rate (YoY) | 142.6% |
| Total Assets | $302.15 Million |
| Market Capitalization | $1.46 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Mind Medicine Inc's assets at a significant premium ( 4.83x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Mind Medicine Inc's assets grew by 142.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Mind Medicine Inc (2015–2024)
The table below shows the annual total assets of Mind Medicine Inc from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $302.15 Million | +142.61% |
| 2023-12-31 | $124.54 Million | -26.74% |
| 2022-12-31 | $169.99 Million | +3.65% |
| 2021-12-31 | $164.00 Million | +101.18% |
| 2020-12-31 | $81.52 Million | +2675.66% |
| 2019-12-31 | $2.94 Million | -16.87% |
| 2018-12-31 | $3.53 Million | -12.28% |
| 2017-12-31 | $4.03 Million | +1886.43% |
| 2016-12-31 | $202.75K | -30.48% |
| 2015-12-31 | $291.66K | -- |